DUSA Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, DUSA Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

DUSA Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.

DUSA Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Keratosis, Actinic, with 1 trials.

Top-decile sponsor footprint

DUSA Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face

NCT02632110
COMPLETED Phase 2

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

NCT02628236
COMPLETED Phase 2

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

NCT02281136
COMPLETED Phase 2

Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

NCT02239679
COMPLETED

Twelve Month Follow-Up of CP0108

NCT02209012
COMPLETED Phase 3

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

NCT02137785
COMPLETED Phase 2

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
COMPLETED Phase 2

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

NCT01458587
TERMINATED Phase 2

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
COMPLETED Phase 2

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433

Phase Distribution

PhaseTrial count
Phase 2 8
Phase 3 1

Therapeutic Areas

Keratosis, Actinic 1
Acne Vulgaris 1

How the DUSA Pharmaceuticals early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Keratosis, Actinic (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

DUSA Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

DUSA Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share DUSA PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
DUSA Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

DUSA Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this DUSA Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of DUSA Pharmaceuticals or any single study.

  • None of DUSA Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Keratosis, Actinic is the condition DUSA Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Keratosis, Actinic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. DUSA Pharmaceuticals pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.